Iambic Therapeutics said on Monday early-stage data of its experimental drug showed anti-tumor activity in heavily pretreated cancer patients with mutations in the HER2 gene. The drug IAM1363, ...
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback